Restructuring will likely be slow for FDA and CDER

09/20/2013 | PharmTech.com

A push by the FDA's Center for Drug Evaluation and Research to establish an Office of Pharmaceutical Quality early next year is unlikely to be accomplished quickly, Jill Wechsler writes. The Office of Management and Budget and HHS officials will review the proposal, and some members of Congress could weigh in as well on its impact on access to drugs and shortages of treatments, she writes.

View Full Article in:

PharmTech.com